Connect with us
Moderna closed 2022 with a profit of $8.36 billion, which represents a decrease of 31% compared to the previous year. Moderna argues this decrease to the...
Moderna has made the announcement of new vaccines with its mRNA technology. In addition to Covid-19, the company is working with Merck on a skin cancer vaccine...
Moderna considers Spain to be a key market due to its access to talent, business environment, and the quality of infrastructure, as well as the government's...
As vaccine sales for Novavax, Moderna, and BioNTech shift in line with a changing Covid-19 situation, the results are being felt in the stock markets. Here...
Moderna is now advancing two bivalent candidates for fall, based on differing market preferences for Omicron subvariants. The bivalent booster mRNA-1273.214 is the only candidate that...
Moderna's commitment to Spain was made clear last Tuesday, June 7th, when representatives of the US biotech company met with the President of the Government, Pedro...
Pfizer closed the first quarter of 2022 with a profit of $7.86 billion, up from $4.88 billion collected between January and March 2021. The pharma developer...
In ten years since its inception, Moderna has transformed from a research-stage company advancing programs in the messenger RNA (mRNA) field to a company with a...
Moderna closed 2021 with a profit of $12.2 billion, compared to a loss of $747 million recorded in 2020. Moderna's total revenue in 2021 was $18.471...
In the fourth quarter of 2021, Moderna achieved a profit of $4.87 billion compared with a loss of $272 million in 2020. Total revenue increased from...